# A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

> **NCT01210846** · PHASE1 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** tivozanib

## Key facts

- **NCT ID:** NCT01210846
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2011-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01210846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01210846, "A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01210846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*